The White House issued a statement of support for an FDA reauthorization bill on Thursday. “The administration strongly supports passage of S. 3187, the Food and Drug Administration Safety and Innovation Act, which will help speed safe and effective drugs, medical devices and bio-similar biological products to patients,” a statement from the Office of Management and Budget released Thursday read. On Thursday, the Senate began consideration of the legislation, the Federal Food, Drug and Cosmetic Act, which creates a program where certain drug manufactures pay user-fees as part of the product-review process. The bill also increases the FDA’s user-fee program related to medical technology and certain prescription drugs.
